ReviewJournal of cancer research and clinical oncology2014
Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society.
Review in Journal of cancer research and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Characteristics of sphingomyelin metabolism in the MCF7 and BT474 radiotherapy‑resistant HER2‑positive breast cancer cell lines.Oncology letters · 2024Article
- Breast Cancer Stem Cell Membrane Biomarkers: Therapy Targeting and Clinical Implications.Cells · 2022Review
- Proton pump inhibitors and sensitization of cancer cells to radiation therapy.Frontiers in oncology · 2022Review
- The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells.Cell death discovery · 2021Article
- Anthelminthic niclosamide inhibits tumor growth and invasion in cisplatin-resistant human epidermal growth factor receptor 2-positive breast cancer.Oncology letters · 2021Article
- Signaling pathways governing breast cancer stem cells behavior.Stem cell research & therapy · 2021Review
- Metabolism and immunity in breast cancer.Frontiers of medicine · 2021Review
- Properties and gene expression profiling of acquired radioresistance in mouse breast cancer cells.Annals of translational medicine · 2021Article
- The Target Differences of Anti-Tumorigenesis Potential of Curcumin and its Analogues Against HER-2 Positive and Triple-Negative Breast Cancer Cells.Advanced pharmaceutical bulletin · 2021Article
- EGFR Expression in HER2-Driven Breast Cancer Cells.International journal of molecular sciences · 2020Article
- Caspase-3 knockout attenuates radiation-induced tumor repopulation via impairing the ATM/p53/Cox-2/PGEAging · 2020Article
- Learning common and specific patterns from data of multiple interrelated biological scenarios with matrix factorization.Nucleic acids research · 2019Article
- Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells.Nature communications · 2019Article
- Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms.Journal of hematology & oncology · 2019Review
- Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance.Cancer letters · 2019Review
- Oncogenic transformation of normal breast epithelial cells co-cultured with cancer cells.Cell cycle (Georgetown, Tex.) · 2018Article
- Chromatin remodeling modulates radiosensitivity of the daughter cells derived from cell population exposed to low- and high-LET irradiation.Oncotarget · 2017Article
- Targeted therapies in breast cancer: New challenges to fight against resistance.World journal of clinical oncology · 2017Review
- Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A).Oncotarget · 2016Article
- All-trans retinoic acids induce differentiation and sensitize a radioresistant breast cancer cells to chemotherapy.BMC complementary and alternative medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
purposeThe lethal effects of cancer are associated with the enhanced tumor aggressiveness in recurrent and metastatic lesions that show resistant phenotype to anti-cancer therapy, a major barrier to improving overall survival of cancer patients. The presence of heterogeneous populations of cancer cells within a specific tumor including the tumor-initiating cells or so-called cancer stem cells (CSCs) has linked the acquired resistance (AR, or adaptive resistance). Herein, we discuss the CSC-mediated tumor repopulation in AR of breast cancer in this review.
methodsWe emphasize a dynamic feature of gene induction in tumor cells that undergo long-term treatment, and describe a specific HER2-NF-κB-HER2 pro-survival pathway that can be initiated in breast CSCs upon radiation therapy.
resultsElucidation of HER2-induced pro-survival networks, specifically the force driving tumor repopulation due to radioresistant CSCs during anticancer therapies, will have a significant impact on the generation of new diagnostic and therapeutic targets to control of recurrent and metastatic breast tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.